Drug Profile
Research programme: ion channel modulators - Xenon Pharmaceuticals
Alternative Names: Nav1.2/1.6 dual modulators - Xenon Pharmaceuticals; Nav1.6 modulators - Xenon Pharmaceuticals; Sodium channel modulators - Xenon PharmaceuticalsLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Xenon Pharmaceuticals
- Class Antiepileptic drugs
- Mechanism of Action Ion channel modulators; NAV1.1 voltage-gated sodium channel stimulants; NAV1.2 voltage-gated sodium channel modulators; Nav1.6 voltage-gated sodium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dravet syndrome; Epilepsy
Most Recent Events
- 22 Sep 2023 Discontinued - Preclinical for Epilepsy in USA (unspecified route)
- 22 Sep 2023 Discontinued for Dravet syndrome in USA (unspecified route)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Epilepsy in USA